-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Analyzing Cue Health (NASDAQ:HLTH) and Nautilus Biotechnology (NASDAQ:NAUT)
Analyzing Cue Health (NASDAQ:HLTH) and Nautilus Biotechnology (NASDAQ:NAUT)
Cue Health (NASDAQ:HLTH – Get Rating) and Nautilus Biotechnology (NASDAQ:NAUT – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Cue Health and Nautilus Biotechnology, as provided by MarketBeat.com.
Get Cue Health alerts:| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cue Health | 0 | 1 | 3 | 0 | 2.75 |
| Nautilus Biotechnology | 0 | 2 | 0 | 0 | 2.00 |
Cue Health currently has a consensus price target of $7.00, suggesting a potential upside of 139.73%. Nautilus Biotechnology has a consensus price target of $4.00, suggesting a potential upside of 158.06%. Given Nautilus Biotechnology's higher possible upside, analysts plainly believe Nautilus Biotechnology is more favorable than Cue Health.
Insider and Institutional Ownership
37.9% of Cue Health shares are owned by institutional investors. Comparatively, 46.1% of Nautilus Biotechnology shares are owned by institutional investors. 29.4% of Cue Health shares are owned by insiders. Comparatively, 41.3% of Nautilus Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.Profitability
This table compares Cue Health and Nautilus Biotechnology's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cue Health | -24.25% | -12.29% | -8.93% |
| Nautilus Biotechnology | N/A | -17.79% | -16.17% |
Risk & Volatility
Cue Health has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, Nautilus Biotechnology has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.
Valuation & Earnings
This table compares Cue Health and Nautilus Biotechnology's top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cue Health | $618.11 million | 0.71 | $86.42 million | ($0.88) | -3.32 |
| Nautilus Biotechnology | N/A | N/A | -$50.31 million | ($0.49) | -3.16 |
Cue Health has higher revenue and earnings than Nautilus Biotechnology. Cue Health is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.
Summary
Cue Health beats Nautilus Biotechnology on 7 of the 13 factors compared between the two stocks.
About Cue Health
(Get Rating)
Cue Health Inc., a healthcare technology company, designs and develops diagnostic platform for diagnostic tests for individuals, enterprises, healthcare providers and payors, and public health agencies. The company offers Cue Integrated Care platform comprising hardware and software components, such as Cue Health Monitoring System consisting of Cue Reader, a portable and reusable reader, Cue Cartridge, a single-use test cartridge, and Cue Wand, a sample collection wand; Cue Data and Innovation Layer, a solution with cloud-based data and analytics capability; Cue Virtual Care Delivery Apps, which include Cue Health App and Cue Enterprise Dashboard; and Cue Ecosystem Integrations and Apps, a solution that allows integrations with third-party applications and sensors. It also provides COVID-19 testing kits for the Cue Health Monitoring System The company was formerly known as Cue Inc and changed its name to Cue Health Inc. in December 2017. Cue Health Inc. was incorporated in 2010 and is headquartered in San Diego, California.
About Nautilus Biotechnology
(Get Rating)
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
Receive News & Ratings for Cue Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Health and related companies with MarketBeat.com's FREE daily email newsletter.
Cue Health (NASDAQ:HLTH – Get Rating) and Nautilus Biotechnology (NASDAQ:NAUT – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.
CUE Health(納斯達克：HLTH-GET評級)和鸚鵡螺生物科技(納斯達克：NAUT-GET評級)都是小盤醫療公司，但哪種投資更好？我們將根據兩家公司的股息、風險、機構持股、分析師建議、收益、估值和盈利能力來比較它們的實力。
Analyst Recommendations
分析師建議
This is a breakdown of current ratings and recommmendations for Cue Health and Nautilus Biotechnology, as provided by MarketBeat.com.
這是由MarketBeat.com提供的對Cue Health和Nautilus Biotech的當前評級和推薦的細分。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cue Health | 0 | 1 | 3 | 0 | 2.75 |
| Nautilus Biotechnology | 0 | 2 | 0 | 0 | 2.00 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 球杆健康 | 0 | 1 | 3 | 0 | 2.75 |
| 鸚鵡螺生物技術 | 0 | 2 | 0 | 0 | 2.00 |
Cue Health currently has a consensus price target of $7.00, suggesting a potential upside of 139.73%. Nautilus Biotechnology has a consensus price target of $4.00, suggesting a potential upside of 158.06%. Given Nautilus Biotechnology's higher possible upside, analysts plainly believe Nautilus Biotechnology is more favorable than Cue Health.
Cue Health目前的共識目標價為7美元，暗示潛在漲幅為139.73。鸚鵡螺生物技術公司的一致目標價為4.00美元，這意味着潛在的上漲幅度為158.06。考慮到鸚鵡螺生物技術更有可能的上行空間，分析師們顯然認為鸚鵡螺生物技術比Cue Health更有利。
Insider and Institutional Ownership
內部人與機構持股
Profitability
盈利能力
This table compares Cue Health and Nautilus Biotechnology's net margins, return on equity and return on assets.
此表比較了Cue Health和Nautilus Biotech的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Cue Health | -24.25% | -12.29% | -8.93% |
| Nautilus Biotechnology | N/A | -17.79% | -16.17% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 球杆健康 | -24.25% | -12.29% | -8.93% |
| 鸚鵡螺生物技術 | 不適用 | -17.79% | -16.17% |
Risk & Volatility
風險與波動性
Cue Health has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, Nautilus Biotechnology has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.
Cue Health的貝塔係數為1.12，這意味着其股價的波動性比標準普爾500指數高12%。相比之下，鸚鵡螺生物技術公司的貝塔係數為0.84，這意味着其股價的波動性比標準普爾500指數低16%。
Valuation & Earnings
估值與收益
This table compares Cue Health and Nautilus Biotechnology's top-line revenue, earnings per share (EPS) and valuation.
該表格比較了Cue Health和Nautilus Biotech的營收、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cue Health | $618.11 million | 0.71 | $86.42 million | ($0.88) | -3.32 |
| Nautilus Biotechnology | N/A | N/A | -$50.31 million | ($0.49) | -3.16 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 球杆健康 | 6.1811億美元 | 0.71 | 8642萬美元 | ($0.88) | -3.32 |
| 鸚鵡螺生物技術 | 不適用 | 不適用 | -5,031萬元 | ($0.49) | -3.16 |
Cue Health has higher revenue and earnings than Nautilus Biotechnology. Cue Health is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.
Cue Health的收入和收益高於鸚鵡螺生物技術公司。Cue Health的市盈率低於鸚鵡螺生物科技，表明它目前是兩隻股票中更負擔得起的一隻。
Summary
摘要
Cue Health beats Nautilus Biotechnology on 7 of the 13 factors compared between the two stocks.
Cue Health在兩隻股票之間進行比較的13個因素中，有7個超過了Nautilus Biotech。
About Cue Health
關於Cue Health
(Get Rating)
(獲取評級)
Cue Health Inc., a healthcare technology company, designs and develops diagnostic platform for diagnostic tests for individuals, enterprises, healthcare providers and payors, and public health agencies. The company offers Cue Integrated Care platform comprising hardware and software components, such as Cue Health Monitoring System consisting of Cue Reader, a portable and reusable reader, Cue Cartridge, a single-use test cartridge, and Cue Wand, a sample collection wand; Cue Data and Innovation Layer, a solution with cloud-based data and analytics capability; Cue Virtual Care Delivery Apps, which include Cue Health App and Cue Enterprise Dashboard; and Cue Ecosystem Integrations and Apps, a solution that allows integrations with third-party applications and sensors. It also provides COVID-19 testing kits for the Cue Health Monitoring System The company was formerly known as Cue Inc and changed its name to Cue Health Inc. in December 2017. Cue Health Inc. was incorporated in 2010 and is headquartered in San Diego, California.
CUE Health Inc.是一家醫療保健技術公司，為個人、企業、醫療保健提供者和付款人以及公共衞生機構設計和開發診斷測試診斷平臺。該公司提供由硬件和軟件組件組成的Cue集成護理平臺，例如由Cue Reader(便攜式可重複使用的讀取器)、Cue Cartridge(一次性測試墨盒)和Cue Wand(樣本採集棒)組成的Cue Health Monitor System；Cue Data and Innovation Layer，具有基於雲的數據和分析能力的解決方案；Cue虛擬護理交付應用，包括Cue Health App和Cue Enterprise Dashboard；以及Cue Ecoessis集成和應用，允許與第三方應用和傳感器集成。它還為CUE健康監測系統提供新冠肺炎檢測試劑盒，該公司前身為CUE Inc.，並於2017年12月更名為Cue Health Inc.。CUE Health Inc.成立於2010年，總部設在加利福尼亞州聖地亞哥。
About Nautilus Biotechnology
關於鸚鵡螺生物技術
(Get Rating)
(獲取評級)
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
鸚鵡螺生物技術公司是一家處於發展階段的生命科學公司，致力於創建一種量化和解鎖蛋白質組複雜性的平臺技術。它開發了Nautilus Platform，這是一個蛋白質組學平臺，包括由儀器、消耗品和軟件分析組成的端到端解決方案。該公司成立於2016年，總部位於華盛頓州西雅圖。
Receive News & Ratings for Cue Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Health and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《Cue Health Daily》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Cue Health和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧